An interventional study of Thiamine in Dry Beriberi, sponsored by Chittagong Medical College. Completed at 1 site in Bangladesh. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-27.
Sponsored by Chittagong Medical College · Not applicable, Interventional, and Treatment
Abstract Background: Thiamine deficiency related disorders are increasingly being reported in countries where polished rice is the main dietary constituents and diet is not balanced in calorie, protein and micronutrients contents. Thiamine deficiency often associated with a sensory-motor neuropathy (dry beriberi) without Wernicke's encephalopathy and cardiac dysfunction.
Objectives: The objective of our study will be to evaluate the efficacy of thiamine in patients with clinically suspected dry beriberi.
Methods: This study will be a prospective, open labeled, self-controlled clinical trial (quasi-experimental study) carried out in the Neurology and Medicine Ward of Chittagong Medical College Hospital from July 2018 to June 2019. Fifty-five (55) patients of suspected dry beriberi will be recruited as per inclusion and exclusion criteria. All patients will be given 200mg IV Thiamine Hydrochloride per day for 1 week, then oral Tab. Thiamine 100mg twice daily for remaining 11week. They will be evaluated clinically before treatment and followed up at the end of 1 week, 6 week and 12 week after treatment. Assessment will be done by some clinical parameters like leg swelling, muscle cramp, muscle power, squat test, sensory impairments, deep tendon reflexes and by Overall Neuropathy Limitations Scale (ONLS) Score. Pre and post test treatment data will be recorded in a pre-designed case record form. To determine whether any o the difference between pretreatment and post treatment values were statistically significant or not, either Friedman's test or Cochran's Q test will be used. Analysis will be performed with SPSS windows version 23 and statistical significance will be defined as P\<0.05 and confidence interval will be set at 95% level. Our study result is likely to sensitize the health professionals of this region about this neglected health issue by increasing awareness of the clinical spectrum of Thiamine Deficiency related Peripheral Neuropathy.
This Self-controlled Clinical Trial will be conducted in Department of Neurology and Department of Medicine of Chittagong Medical College Hospital (CMCH) during July 2018 to June 2019. A total of 55 patients of possible beriberi will be included based on inclusion criteria. Patients with isolated cardiac/wet beriberi and with other known causes of peripheral neuropathy such as Diabetic, hereditary, Demyelinating (GBS, CIDP), metabolic (hepatic/renal impairment), history of intake of drugs (e.g. INH, Ethambutol, Phenytoin, Metronidazole, Dapsone etc.) and toxins exposure (As ,Organo-phosphate Compound, Pb ,Hg except alcohol) were excluded from study.
Operational Definitions:
Risk factors: Imbalanced diet (diet poor in thiamine/rich in carbohydrate or anti-thiamine factors), malnutrition, alcoholism, Gastro-Intestinal surgery, chronic diarrhoea, chronic vomiting, pregnancy or history of recent delivery, chronic, diuretics use, renal dialysis, total parenteral nutrition.
Possible/suspected neuritic (dry) beriberi: Risk factors + at least 2 of the following signs:
Data collection Procedure: After selection of subjects, detailed history, clinical examination and all other Information regarding sociodemographic and clinical factors of neuritic beriberi will be taken in a prescribed case record form. Relevant investigations (CBC, Peripheral Blood Flim (PBF), Serum creatinine, serum electrolytes, Liver function test, fasting \& 2 hour after breakfast sugar. HbA1C, TSH, serum Vitamin B12, Chest X ray, ECG, Echocardiography, CSF study, Nerve Conduction Study will be performed to exclude differential diagnoses. Then therapeutic trial of Inj. Thiamine will be given IV for 1st week (200mg IV daily) then orally (tab. Thiamin 100mg bd) for 11 weeks. Patients will be followed up after 1, 6 and 12 week to see the response on the basis of some clinical parameters and Overall Neuropathy Limitations Scale (ONLS) score.
Statistical Analysis: Continuous data will be reported as the means ± SD or median and interquartile range. Qualitative or categorical data will be described as frequencies and proportions. The intention to treat analysis (ITT) analysis will be used to determine the statistical significance. Missing values will be replaced by the series means for this purpose. To determine whether any of the difference between pretreatment and post treatment values are statistically significant or not, either Friedman's test or Cochran's Q test will be used. Former test compares the quantitative variables and non-dichotomous qualitative variables and the later test compares the dichotomous qualitative/categorical variables. Statistical significance will be defined as P \< 0.05 and confidence interval will be set at 95% level.
Variables under study:
Primary Outcome Variable: Treatment response will be measured by Overall Neuropathy Limitation Scale (ONLS) score before and after treatment.
Secondary Outcome Variables: Comparison and Assessment of clinical features at presentation and after treatment: leg swelling, muscle cramp, muscle power (MRC grading), deep tendon reflexes, sensory impairments (tingling /burning /pain/ touch/ position /vibration), squat test.
This study has received approval from Ethical Review Committee of Chittagong Medical College and written informed concent.will be taken from all participants.
11 studies on the registry are indexed under Beriberi; none are open to participants now.
Browse Beriberi studies →Chittagong Medical College is the lead sponsor of 15 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Any person admitted to CMCH as a Suspected thiamine deficiency related peripheral Neuropathy / Possible dry-beriberi:
Risk factors + at least 2 of the following signs:
Risk factors include Imbalanced diet (diet poor in thiamine/rich in carbohydrate or anti-thiamine factors), malnutrition, alcoholism, Gastrointestinal surgery, chronic diarrhoea, chronic vomiting, pregnancy or history of recent delivery, chronic. diuretics use, renal dialysis, total parenteral nutrition.
Exclusion Criteria:
its a quasi experimental study where single group is used (self controlled clinical trial). clinical features were compared before iand after intervention
Dietary Supplement: Thiamine
Injection Thiamine 200 mg daily intravenously for 1 week followed by Tablet Thiamine 100mg bid for remaining 11 weeks
change in Overall Neuropathy Limitation Scale (ONLS) score
it is score measuring functional status of peripheral neuropathy patients. lowest score is 0 (No disability) and highest score 12 (most disability)
Time frame: before treatment with Thiamine (baseline ) and after 1 week, 6week, 12 week of treatment
change in leg swelling
it may be mild (pitting disappears immediately after removing finger pressure), moderate (requiring less than 30 seconds to disappear after giving pressure), severe (requiring more than 30 seconds to disappear after giving pressure)
Time frame: before treatment with Thiamine (baseline ) and after 1 week, 6week, 12 week of treatment
change in muscle power
Medical Research Council (MRC) score is used, highest score 5 (Normal Power) and lowest score 0 (No muscle power)
Time frame: before treatment with Thiamine (baseline ) and after 1 week, 6week, 12 week of treatment
change in muscle cramp
Visual Analogue Scale (VAS) will be used for assessing severity of Muscle cramp. no cramp=0, mild cramp=1 to 3, moderate cramp= 4 to 6, severe cramp =7 to 10.
Time frame: before treatment with Thiamine (baseline ) and after 1 week, 6week, 12 week of treatment
change in deep tendon reflexes
deep tendon reflexes may be Normal , diminished or absent.
Time frame: before treatment with Thiamine (baseline ) and after 1 week, 6week, 12 week of treatment
change in squat test
squat test may be positive (inability or difficulty in raising from sitting position) or negative (no difficulty )
Time frame: before treatment with Thiamine (baseline ) and after 1 week, 6week, 12 week of treatment
change in pain sensation
Visual Analogue Scale (VAS) will be used for assessing severity of pain. no pain=0, mild pain= 1 to 3, moderate pain= 4 to 6, severe pain= 7 to 10.
Time frame: before treatment with Thiamine (baseline ) and after 1 week, 6week, 12 week of treatment
change in position sensation
it may be Normal , diminished or absent.
Time frame: before treatment with Thiamine (baseline ) and after 1 week, 6week, 12 week of treatment
change in vibration sensation
it may be Normal , diminished or absent.
Time frame: before treatment with Thiamine (baseline ) and after 1 week, 6week, 12 week of treatment
change in touch sensation
it may be Normal , diminished or absent.
Time frame: before treatment with Thiamine (baseline ) and after 1 week, 6week, 12 week of treatment
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2018 to primary completion in Apr 2019, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Thiamine
Chittagong Medical College